Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans

FEMS Yeast Research

Volumn 13, Issue 4, 2013, Pages 386-393

  Xiang, Ming Jie ^a   Liu, Jin Yan ^a   Ni, Pei Hua ^a   Wang, Shengzheng ^b   Shi, Ce ^a   Wei, Bing ^a   Ni, Yu Xing ^a   Ge, Hai Liang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Amino acid substitutions in ERG11 gene; Azole antifungal resistance; Candida albicans; Heterologous expression; Site directed mutagenesis

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ERG11; UNCLASSIFIED DRUG; VORICONAZOLE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FEMALE; FUNGUS ISOLATION; GENE AMPLIFICATION; GENE SEQUENCE; HETEROLOGOUS EXPRESSION; HUMAN; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; CYTOCHROME P-450 ENZYME SYSTEM; DNA MUTATIONAL ANALYSIS; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA;

CANDIDA ALBICANS; SACCHAROMYCES CEREVISIAE;

EID: 84877642562     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/1567-1364.12042     Document Type: Article

References (31)

1. Bellamine A, Lepesheva GI & Waterman MR (2004) Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J Lipid Res 45: 2000-2007.
2. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D & McNicholas PM (2004) Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48: 2124-2131.
3. Chen SH, Sheng CQ, Xu XH, Jiang YY, Zhang WN & He C (2007) Identification of Y118 amino acid residue in Candida albicans sterol 14alpha-demethylase associated with the enzyme activity and selective antifungal activity of azole analogues. Biol Pharm Bull 30: 1246-1253.
4. CLSI (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, 2nd edn. CLSI, Pennsylvania.
5. Cowen LE & Steinbach WJ (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747-764.
6. Feng LJ, Wan Z, Wang XH, Li RY & Liu W (2010) Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene. Chin Med J (Engl) 123: 544-548.
7. Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, Godoy Martinez PC, Goldman MH & Colombo AL (2004) Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 50: 25-32.
8. Ji H, Zhang W, Zhou Y, Zhang M, Zhu J, Song Y & Lü J (2000) A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 43: 2493-2505.
9. Kakeya H, Miyazaki Y, Miyazaki H, Nyswaner K, Grimberg B & Bennett JE (2000) Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 44: 2985-2990.
10. Kontoyiannis DP, Marr KA, Park BJ et al. (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091-1100.
11. Lamb DC, Kelly DE, Schunck WH, Shydehi AZ, Akhtar M, Lowe DJ, Baldwin BC & Kelly SL (1997) The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 272: 5682-5688.
12. Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D & McNicholas PM (2004) Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 53: 74-80.
13. Löffler J, Kelly SL, Hebart H, Schumacher U, Lass-Flörl C & Einsele H (1997) Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151: 263-268.
14. Maebashi K, Kudoh M, Nishiyama Y, Makimura K, Uchida K, Mori T & Yamaguchi H (2002) A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol 46: 317-326.
15. Manasti{dotless}r L, Ergon MC & Yücesoy M (2011) Investigation of mutations in Erg11 gene of fluconazole resistant Candida albicans isolates from Turkish hospitals. Mycoses 54: 99-104.
16. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FC, Odds FC & Bossche HV (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145: 2701-2713.
17. Morio F, Loge C, Besse B, Hennequin C & Le Pape P (2010) Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66: 373-384.
18. Pappas PG, Alexander BD, Andes DR et al. (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101-1111.
19. Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D & Patterson TF (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676-2684.
20. Podust LM, Poulos TL & Waterman MR (2001) Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. P Natl Acad Sci USA 98: 3068-3073.
21. Richardson MD (2005) Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56(suppl 1): i5-i11.
22. Rogers T (2006) Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 27(suppl 1): 7-11.
23. Sanglard D (2002) Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 20: 462-469.
24. Sanglard D, Ischer F, Koymans L & Bille J (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42: 241-253.
25. Sheng C, Ji H, Miao Z, Che X, Yao J, Wang W, Dong G, Guo W, Lu J & Zhang W (2009a) Homology modeling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into rational inhibitor design. J Comput Aided Mol Des 23: 375-389.
26. Sheng C, Miao Z, Ji H, Yao J, Wang W, Che X, Dong G, Lu J, Guo W & Zhang W (2009b) Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding. Antimicrob Agents Chemother 53: 3487-3495.
27. Sheng C, Wang W, Che X, Dong G, Wang S, Ji H, Miao Z, Yao J & Zhang W (2010) Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization. ChemMedChem 5: 390-397.
28. Tan TY, Tan AL, Tee NW & Ng LS (2008) A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore 37: 835-840.
29. Vandeputte P, Ferrari S & Coste AT (2012) Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012: 713687.
30. White TC, Holleman S, Dy F, Mirels LF & Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713.
31. Xu Y, Chen L & Li C (2008) Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61: 798-804.